Evaluating the SUBLOCADE Treatment Exit Strategy
About the study
The purpose of this study is to observe and assess the successful taper and opioid withdrawal experience after participants stop receiving SUBLOCADE because their healthcare provider determines their disease symptoms have been controlled for at least 9 months and they, together with their healthcare provider, plan to discontinue MOUD.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria
EXCLUSION CRITERIA
Participants must meet all of the following criteria:
* The participant, together with their healthcare provider (the investigator), have previously determined that it is appropriate to stop MOUD treatment, and the participant meets the following criteria:
- Has been treated with at least 12 injections of SUBLOCADE.
- In the opinion of the investigator, has had their OUD symptoms (ie, overdose, illicit/nonmedical use, withdrawal) controlled for at least 9 months.
- In the opinion of the investigator, has had any other substance use disorder (excluding alcohol, nicotine, or cannabis) symptoms controlled for at least 9 months.
- Is willing to complete the Baseline Visit 4 to 8 weeks after the last dose of SUBLOCADE.
- Has signed the ICF and is 18 years of age or older.
- Is not currently using opioids to treat a diagnosis other than OUD.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Opioid Use Disorder
Age
18+
Participants Needed
50
Est. Completion Date
Sep 30, 2024
Treatment Type
OBSERVATIONAL
Sponsor
Indivior Inc.
ClinicalTrials.gov NCT Identifier
NCT05878210
Study Number
INDV-6000-407
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?